Skip to content
2000
Volume 32, Issue 7
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background

Sorafenib is a first-line treatment for patients with advanced hepatocellular carcinoma (HCC), but its clinical efficacy is often compromised by the acquisition of drug resistance. Various cancers, including HCC, are affected by long non-coding RNA (lncRNA), but the mechanisms underlying HCC sorafenib resistance have not been extensively studied. This article aims to summarize the recently reported pathways associated with sorafenib resistance and discusses potential applications for the treatment of HCC.

Methods

Relevant studies on the resistance of HCC to anti-tumor drugs were retrieved from PubMed. Given the compelling evidence that sorafenib is an effective treatment for advanced HCC, we analyzed the research papers on lncRNA and sorafenib resistance in HCC in the PubMed system in the past decade and found that lncRNA may be involved in sorafenib resistance in HCC through multiple pathways.

Results

lncRNA is widely involved in the resistance mechanism of HCC to sorafenib. Recent studies have revealed that numerous lncRNAs, such as NEAT1, affect the sensitivity of HCC to sorafenib through various mechanisms, including autophagy and AKT signaling pathways.

Conclusion

lncRNAs play a pivotal role in modulating HCC resistance to sorafenib. And lncRNA is expected to become a new solution to the resistance of sorafenib and other targeted drugs.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128371240250619102820
2025-07-08
2026-03-01

  • From This Site

    /content/journals/cpd/10.2174/0113816128371240250619102820
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. VogelA. MeyerT. SapisochinG. SalemR. SaborowskiA. Hepatocellular carcinoma.Lancet2022400103601345136210.1016/S0140‑6736(22)01200‑4 36084663
     [Google Scholar]
  2. YauT. ParkJ.W. FinnR.S. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial.Lancet Oncol.2022231779010.1016/S1470‑2045(21)00604‑5 34914889
     [Google Scholar]
  3. HaoS.H. MaX.D. XuL. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma.Drug Resist. Updat.20247310105210.1016/j.drup.2024.101052
     [Google Scholar]
  4. LiY. YangW. ZhengY. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.J. Exp. Clin. Cancer Res.2023421610.1186/s13046‑022‑02567‑z 36604718
     [Google Scholar]
  5. WangS. YouX. LiuX. SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.iScience202326710699410.1016/j.isci.2023.106994 37534166
     [Google Scholar]
  6. WangY. WangM. ChenJ. The gut microbiota reprograms intestinal lipid metabolism through long noncoding RNA Snhg9.Science2023381666085185710.1126/science.ade0522 37616368
     [Google Scholar]
  7. YuanK. LanJ. XuL. Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling.Mol. Cancer202221110510.1186/s12943‑022‑01578‑w 35477447
     [Google Scholar]
  8. WangF. HuY. WangH. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.J. Exp. Clin. Cancer Res.202342126710.1186/s13046‑023‑02847‑2 37840133
     [Google Scholar]
  9. ChenD. WangJ. LiY. LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11‐dependent repression of CDKN2A.Clin. Transl. Med.2023139e141810.1002/ctm2.1418 37752791
     [Google Scholar]
  10. YoussefK.K. NietoM.A. Epithelial–mesenchymal transition in tissue repair and degeneration.Nat. Rev. Mol. Cell Biol.202425972073910.1038/s41580‑024‑00733‑z 38684869
     [Google Scholar]
  11. JianH.Y. ZhangJ.T. LiuZ. ZhangZ. ZengP.H. Amentoflavone reverses epithelial‐mesenchymal transition in hepatocellular carcinoma cells by targeting p53 signalling pathway axis.J. Cell. Mol. Med.20242811e1844210.1111/jcmm.18442 38842135
     [Google Scholar]
  12. LiF. WangJ. YanY. BaiC. GuoJ. CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway.BMC Cancer2023231121410.1186/s12885‑023‑11724‑2 38066486
     [Google Scholar]
  13. LiuY. HanT. WuJ. SPOCK1, as a potential prognostic and therapeutic biomarker for lung adenocarcinoma, is associated with epithelial-mesenchymal transition and immune evasion.J. Transl. Med.202321190910.1186/s12967‑023‑04616‑3 38087364
     [Google Scholar]
  14. ChenB.W. ZhouY. WeiT. lncRNA‐POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR‐182‐5p.J. Cell. Biochem.2021122113014210.1002/jcb.29844 32951268
     [Google Scholar]
  15. ZhangP.F. WangF. WuJ. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR‐128/CD151 pathway in hepatocellular carcinoma.J. Cell. Physiol.201923432788279410.1002/jcp.27095 30132868
     [Google Scholar]
  16. LinW.H. ChangY.W. HongM.X. STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis.Oncogene202140479180510.1038/s41388‑020‑01566‑8 33262462
     [Google Scholar]
  17. ZhangY. SongD. PengZ. LINC00891 regulated by miR-128-3p/GATA2 axis impedes lung cancer cell proliferation, invasion and EMT by inhibiting RhoA pathway.Acta Biochim. Biophys. Sin.202254337838710.3724/abbs.2022005 35538035
     [Google Scholar]
  18. SunJ. ZhengX. WangB. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.Acta Biochim. Biophys. Sin.202254226127010.3724/abbs.2021019 35130616
     [Google Scholar]
  19. Sas-ChenA. AureM.R. LeibovichL. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer.EMBO Mol. Med.2016891052106410.15252/emmm.201606198 27485121
     [Google Scholar]
  20. ZengX.Y. XieH. YuanJ. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.Cancer Biol. Ther.201920795696610.1080/15384047.2018.1564567 31062668
     [Google Scholar]
  21. SongJ. LiuQ. HanL. Hsa_circ_0009092/miR-665/NLK signaling axis suppresses colorectal cancer progression via recruiting TAMs in the tumor microenvironment.J. Exp. Clin. Cancer Res.202342131910.1186/s13046‑023‑02887‑8 38008713
     [Google Scholar]
  22. TangH. LongQ. ZhuangK. miR‐665 promotes the progression of gastric adenocarcinoma via elevating FAK activation through targeting SOCS3 and is negatively regulated by lncRNA MEG3.J. Cell. Physiol.202023554709471910.1002/jcp.29349 31650535
     [Google Scholar]
  23. TangX. ZhangW. YeY. LncRNA HOTAIR contributes to sorafenib resistance through suppressing mIR‐217 in hepatic carcinoma.BioMed Res. Int.202020201951507110.1155/2020/9515071 32462038
     [Google Scholar]
  24. GongJ. HanG. ChenZ. CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 Axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer.J. Transl. Med.202422151710.1186/s12967‑024‑05233‑4 38816735
     [Google Scholar]
  25. WangS. TongH. SuT. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR-217 in gallbladder cancer.Cancer Cell Int.202121160810.1186/s12935‑021‑02316‑w 34789260
     [Google Scholar]
  26. VargasJ.N.S. HamasakiM. KawabataT. YouleR.J. YoshimoriT. The mechanisms and roles of selective autophagy in mammals.Nat. Rev. Mol. Cell Biol.202324316718510.1038/s41580‑022‑00542‑2 36302887
     [Google Scholar]
  27. YamamotoH. ZhangS. MizushimaN. Autophagy genes in biology and disease.Nat. Rev. Genet.202324638240010.1038/s41576‑022‑00562‑w 36635405
     [Google Scholar]
  28. WuN. ZhengW. ZhouY. Autophagy in aging-related diseases and cancer: Principles, regulatory mechanisms and therapeutic potential.Ageing Res. Rev.202410010242810.1016/j.arr.2024.102428 39038742
     [Google Scholar]
  29. DebnathJ. GammohN. RyanK.M. Autophagy and autophagy-related pathways in cancer.Nat. Rev. Mol. Cell Biol.202324856057510.1038/s41580‑023‑00585‑z 36864290
     [Google Scholar]
  30. ZhenY. StenmarkH. Autophagosome Biogenesis.Cells202312466810.3390/cells12040668 36831335
     [Google Scholar]
  31. HuangX. YaoJ. LiuL. S-acylation of p62 promotes p62 droplet recruitment into autophagosomes in mammalian autophagy.Mol. Cell2023831934853501.e1110.1016/j.molcel.2023.09.004 37802024
     [Google Scholar]
  32. JingZ. YeX. MaX. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma.Cancer Med.20209124324433810.1002/cam4.3020 32324343
     [Google Scholar]
  33. HuangC. ShuL. ZhangH. ZhuX. HuangG. XuJ. Circ_ZNF512-mediated mir-181d-5p inhibition limits cardiomyocyte autophagy and promotes myocardial ischemia/reperfusion injury through an EGR1/mTORC1/TFEB-based mechanism.J. Med. Chem.20226531808182110.1021/acs.jmedchem.1c00745 35041407
     [Google Scholar]
  34. HayashiM. YamadaS. KurimotoK. miR-23b-3p plays an oncogenic role in hepatocellular carcinoma.Ann. Surg. Oncol.20212863416342610.1245/s10434‑020‑09283‑y 33140250
     [Google Scholar]
  35. LiG. ZhangZ. ChenZ. LiuB. WuH. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway.Life Sci.202127711941910.1016/j.lfs.2021.119419 33785336
     [Google Scholar]
  36. ChenL. SunL. DaiX. LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells.Front. Cell Dev. Biol.2021968752410.3389/fcell.2021.687524 34409031
     [Google Scholar]
  37. SunC. ChenY. GuQ. UBE3C tunes autophagy via ATG4B ubiquitination.Autophagy202420364565810.1080/15548627.2023.2299514 38146933
     [Google Scholar]
  38. LiX. ZhouY. YangL. LncRNA NEAT1 promotes autophagy via regulating miR‐204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.J. Cell. Physiol.202023543402341310.1002/jcp.29230 31549407
     [Google Scholar]
  39. Mallén-PonceM.J. Pérez-PérezM.E. Redox-mediated activation of ATG3 promotes ATG8 lipidation and autophagy progression in Chlamydomonas reinhardtii.Plant Physiol.2023194135937510.1093/plphys/kiad520 37772945
     [Google Scholar]
  40. ZouZ. LiuX. YuJ. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.J. Hepatol.202480683484510.1016/j.jhep.2024.01.029 38331323
     [Google Scholar]
  41. ZhouM. ZhangG. HuJ. Rutin attenuates sorafenib-induced chemoresistance and autophagy in hepatocellular carcinoma by regulating BANCR/miRNA-590-5P/OLR1 axis.Int. J. Biol. Sci.202117133595360710.7150/ijbs.62471 34512168
     [Google Scholar]
  42. DixonS.J. LembergK.M. LamprechtM.R. Ferroptosis: An iron-dependent form of nonapoptotic cell death.Cell201214951060107210.1016/j.cell.2012.03.042 22632970
     [Google Scholar]
  43. LiangD. MinikesA.M. JiangX. Ferroptosis at the intersection of lipid metabolism and cellular signaling.Mol. Cell202282122215222710.1016/j.molcel.2022.03.022 35390277
     [Google Scholar]
  44. YangC. LuT. LiuM. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.Phytomedicine202311115466810.1016/j.phymed.2023.154668 36657316
     [Google Scholar]
  45. LianY. YangJ. LianY. XiaoC. HuX. XuH. DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2.Cancer Commun.201838111110.1186/s40880‑018‑0333‑9 30367681
     [Google Scholar]
  46. ShiZ. LiZ. JinB. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation.Clin. Transl. Med.2023136e130010.1002/ctm2.1300 37337470
     [Google Scholar]
  47. YeY. ChenA. LiL. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification.Kidney Int.202210261259127510.1016/j.kint.2022.07.034 36063875
     [Google Scholar]
  48. JiangT. XiaoY. ZhouJ. Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway.Redox Biol.20236810296310.1016/j.redox.2023.102963
     [Google Scholar]
  49. LiX. LiY. LianP. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.Hum. Exp. Toxicol.202342960327122114281810.1177/09603271221142818
     [Google Scholar]
  50. WangY. YanS. LiuX. PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.Cell Death Differ.202229101982199510.1038/s41418‑022‑00990‑5 35383293
     [Google Scholar]
  51. WangY. ZhengL. ShangW. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer.Cell Death Differ.202229112190220210.1038/s41418‑022‑01008‑w 35534546
     [Google Scholar]
  52. YuQ. ZhangN. GanX. EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p/ACSL4 axis.Phytomedicine202311915499910.1016/j.phymed.2023.154999 37597361
     [Google Scholar]
  53. ZhengY. XuL. HassanM. Bayesian modeling identifies PLAG1 as a key regulator of proliferation and survival in rhabdomyosarcoma cells.Mol. Cancer Res.202018336437410.1158/1541‑7786.MCR‑19‑0764 31757836
     [Google Scholar]
  54. LiJ. LiY. WangD. LiaoR. WuZ. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.J. Exp. Clin. Cancer Res.202443114310.1186/s13046‑024‑03061‑4 38745179
     [Google Scholar]
  55. ChelakkotC. ChelakkotV.S. ShinY. SongK. Modulating glycolysis to improve cancer therapy.Int. J. Mol. Sci.2023243260610.3390/ijms24032606 36768924
     [Google Scholar]
  56. LiM. YuJ. JuL. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer.Cell Death Dis.20241514410.1038/s41419‑024‑06446‑7 38218970
     [Google Scholar]
  57. ZhangX. ZhaoL. YingK. TUG1 protects against ferroptosis of hepatic stellate cells by upregulating PDK4-mediated glycolysis.Chem. Biol. Interact.202338311067310.1016/j.cbi.2023.110673 37582412
     [Google Scholar]
  58. HeY. WangX. LuW. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis.Cell Death Dis.202213211810.1038/s41419‑022‑04576‑4 35121728
     [Google Scholar]
  59. PanM. LuoM. LiuL. EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL.J. Exp. Clin. Cancer Res.20244313510.1186/s13046‑024‑02957‑5 38287371
     [Google Scholar]
  60. LiR. LiS. ShenL. SNHG1, interacting with SND1, contributes to sorafenib resistance of liver cancer cells by increasing m6A‐mediated SLC7A11 expression and promoting aerobic glycolysis.Environ. Toxicol.2023 37927237
     [Google Scholar]
  61. ZhengJ. ZhangQ. ZhaoZ. Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1.J. Exp. Clin. Cancer Res.202342112710.1186/s13046‑023‑02684‑3
     [Google Scholar]
  62. AnY. DuanH. The role of m6A RNA methylation in cancer metabolism.Mol. Cancer20222111410.1186/s12943‑022‑01500‑4 35022030
     [Google Scholar]
  63. BuL. ZhangZ. ChenJ. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.Gut20247371156116810.1136/gutjnl‑2023‑330826 38191266
     [Google Scholar]
  64. YuL. WeiJ. LiuP. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.Semin. Cancer Biol.202285699410.1016/j.semcancer.2021.06.019 34175443
     [Google Scholar]
  65. GuoN. WangX. XuM. BaiJ. YuH. ZhangL. PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression.Pharmacol. Res.202420610730010.1016/j.phrs.2024.107300 38992850
     [Google Scholar]
  66. TufailM. WanW.D. JiangC. LiN. Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer.Chem. Biol. Interact.202439611105510.1016/j.cbi.2024.111055 38763348
     [Google Scholar]
  67. TsuchiyaH. ShinonagaR. SakaguchiH. KitagawaY. YoshidaK. NEAT1-SOD2 axis confers sorafenib and lenvatinib resistance by activating AKT in liver cancer cell lines.Curr. Issues Mol. Biol.20234521073108510.3390/cimb45020071 36826016
     [Google Scholar]
  68. LiW. DongX. HeC. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.J. Exp. Clin. Cancer Res.201938118310.1186/s13046‑019‑1177‑0 31053148
     [Google Scholar]
  69. ZhouY. HuangY. DaiT. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.Biomed. Pharmacother.202113311103010.1016/j.biopha.2020.111030 33378944
     [Google Scholar]
  70. HuY. XuY. ZhangT. Cisplatin-activated ERβ/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis.Drug Resist. Updat.20237110101410.1016/j.drup.2023.101014
     [Google Scholar]
  71. ChenY. XiangD. ZhaoX. ChuX. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance.Hum. Cell20213461800181110.1007/s13577‑021‑00587‑z 34374933
     [Google Scholar]
  72. YangS-j. WangD-d. ZhongS-l. ChenW-q. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis.Cell Death Dis.202112542010.1038/s41419‑021‑03680‑1
     [Google Scholar]
  73. ChengL. DeepakR.N.V.K. WangG. Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis.Hepatology20237861828184210.1097/HEP.0000000000000314 36804859
     [Google Scholar]
  74. FanJ. ToK.K.W. ChenZ.S. FuL. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.Drug Resist. Updat.20236610090510.1016/j.drup.2022.100905 36463807
     [Google Scholar]
  75. SchlessingerA. ZatorskiN. HutchinsonK. ColasC. Targeting SLC transporters: Small molecules as modulators and therapeutic opportunities.Trends Biochem. Sci.202348980181410.1016/j.tibs.2023.05.011 37355450
     [Google Scholar]
  76. HeF. ZhangP. LiuJ. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.J. Hepatol.202379236237710.1016/j.jhep.2023.03.016 36996941
     [Google Scholar]
  77. YangD. LiuH. CaiY. Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression.Cell Rep.202241811169110.1016/j.celrep.2022.111691 36417878
     [Google Scholar]
  78. WangX. ChenY. WangX. Stem Cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11.Cancer Res.202181205217522910.1158/0008‑5472.CAN‑21‑0567 34385181
     [Google Scholar]
  79. ShiC.J. PangF.X. LeiY.H. 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis.Drug Resist. Updat.20257810118110.1016/j.drup.2024.101181 39657434
     [Google Scholar]
  80. ChenQ. ZhengW. GuanJ. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma.Cell Death Differ.202330113715110.1038/s41418‑022‑01051‑7 35995846
     [Google Scholar]
  81. HaratakeN. OzawaH. MorimotoY. MUC1-C Is a common driver of acquired osimertinib resistance in NSCLC.J. Thorac. Oncol.202419343445010.1016/j.jtho.2023.10.017 37924972
     [Google Scholar]
  82. JinW. LiaoX. LvY. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.Cell Death Dis.201788e2980e010.1038/cddis.2017.378 28796259
     [Google Scholar]
  83. TangQ. LiX. ChenY. Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP‐TUG1/miR‐4726‐5p/MUC1 pathway.Mol. Carcinog.202261441743210.1002/mc.23389 35040191
     [Google Scholar]
  84. ChanY.T. WuJ. LuY. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.Mol. Cancer20242317410.1186/s12943‑024‑01988‑y 38582885
     [Google Scholar]
  85. TsengC.F. ChenL.T. WangH.D. LiuY.H. ShiahS.G. Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness.Cancer Sci.202211351601161210.1111/cas.15319 35253323
     [Google Scholar]
  86. WangY. TanK. HuW. HouY. YangG. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.Exp. Cell Res.2022420111333510.1016/j.yexcr.2022.113335 36084669
     [Google Scholar]
  87. ChiX. ChenZ. ChenY. HongH. YuJ. LvL. Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505.J. Biochem. Mol. Toxicol.20233710e2343710.1002/jbt.23437 37352125
     [Google Scholar]
  88. ZhangJ. ZhaoX. MaX. YuanZ. HuM. KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells.Int. J. Mol. Med.20204651794180410.3892/ijmm.2020.4710 33000204
     [Google Scholar]
  89. AL-NoshokatyT.M. MesbahN.M. Abo-ElmattyD.M. AbulsoudA.I. Abdel-HamedA.R. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.Life Sci.202230312067510.1016/j.lfs.2022.120675 35640776
     [Google Scholar]
  90. SongW. ZhengC. LiuM. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.Mol. Ther.20212982601261610.1016/j.ymthe.2021.04.011 33839325
     [Google Scholar]
  91. SuiC. DongZ. YangC. LncRNA FOXD2‐AS1 as a competitive endogenous RNA against miR‐150‐5p reverses resistance to sorafenib in hepatocellular carcinoma.J. Cell. Mol. Med.20192396024603310.1111/jcmm.14465 31210410
     [Google Scholar]
  92. LiuY.T. LiuG.Q. HuangJ.M. FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p-CCNG1 interaction network.Biosci. Rep.20204012BSR2020205410.1042/BSR20202054 33245102
     [Google Scholar]
  93. LiuY.C. LinY.H. ChiH.C. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.Clin. Epigenetics202214110610.1186/s13148‑022‑01326‑3 35999564
     [Google Scholar]
  94. XuY. LiuY. LiZ. Long non coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR 675.Oncol. Rep.202044116517310.3892/or.2020.7608 32627034
     [Google Scholar]
  95. FanL. HuangX. ChenJ. Long noncoding RNA MALAT1 contributes to sorafenib resistance by targeting miR-140-5p/] aurora-a signaling in hepatocellular carcinoma.Mol. Cancer Ther.20201951197120910.1158/1535‑7163.MCT‑19‑0203 32220970
     [Google Scholar]
  96. JinW. ChenL. CaiX. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.Oncol. Rep.201737127328010.3892/or.2016.5248 27878301
     [Google Scholar]
  97. ChenS. XiaX. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR‐335-c‐Met.J. Cell. Physiol.20192349149991500910.1002/jcp.27567 30937906
     [Google Scholar]
  98. BhattacharjeeR. PrabhakarN. KumarL. Crosstalk between long noncoding RNA and microRNA in cancer.Cell. Oncol.202346488590810.1007/s13402‑023‑00806‑9 37245177
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128371240250619102820
Loading
Sorafenib Resistance in Hepatocellular Carcinoma: Emerging Molecular Insights from Long Non-Coding RNAs
Curr. Pharm. Des. 32, 505 (2026); https://doi.org/10.2174/0113816128371240250619102820
/content/journals/cpd/10.2174/0113816128371240250619102820
/content/journals/cpd/10.2174/0113816128371240250619102820
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biomolecular marker; drug resistance; hepatocellular carcinoma; Long non-coding RNAs; microRNAs; sorafenib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test